Literature DB >> 18160576

Kallikrein activates prothrombin.

Thomas W Stief1.   

Abstract

Kallikrein is a multitalented enzyme in hemostasis and inflammation. Normally, kallikrein is formed in intrinsic hemostasis and activates factor XII. A total of 10 microL of 0 to 100 microg/mL human plasma kallikrein in 6% human albumin-PBS were incubated with 90 microL 111.1 microg/mL prothrombin in 6% human albumin in absence and presence of 23 mM Ca(++). After 0 to 64 minutes (37 degrees C), 100 microL of 2.5 M arginine, pH 9, were added. Fifty microliters of 0.72 mM HD-CHG-Ala-Arg-pNA in 1.36 M arginine were added and increase in absorbance at 405 nm was determined. Within 8 minutes (37 degrees C), 1 microg/mL kallikrein, ie, 2.5% of the normal plasmatic prekallikrein concentration, generates approximately 3 mIU/mL thrombin in absence and 27 mIU/mL thrombin in presence of Ca(++). Kallikrein can directly activate prothrombin; there is a shortcut in the intrinsic hemostasis system that generates catalytic amounts of thrombin without following the known intrinsic clotting pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160576     DOI: 10.1177/1076029607308036

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  8 in total

1.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

2.  In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.

Authors:  Anja Kaeberich; Uwe Raaz; Alexander Vogt; Lars Maedgefessel; Eric Neuhart; Chantal Krezel; Ludovic Drouget; Baerbel Hauroeder; Michael Buerke; Karl Werdan; Axel Schlitt
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

3.  Life-threatening cardiac manifestations of primary antiphospholipid syndrome.

Authors:  Rafal Grzybczak; Anetta Undas; Pawel Rostoff; Andrzej Gackowski; Urszula Czubek; Katarzyna Stopyra; Wieslawa Piwowarska
Journal:  Heart Vessels       Date:  2010-05-29       Impact factor: 2.037

Review 4.  Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.

Authors:  Mark Y Chan; Jeffrey I Weitz; Yahye Merhi; Robert A Harrington; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2009-10       Impact factor: 2.300

5.  Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors.

Authors:  Sooyong Park; Ja-Yoon Gu; Hyun Kyung Kim
Journal:  J Thromb Thrombolysis       Date:  2022-01-07       Impact factor: 2.300

6.  Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.

Authors:  François Schiele
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

7.  Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study.

Authors:  Sara Schramm; Martha Jokisch; Karl-Heinz Jöckel; Arne Herring; Kathy Keyvani
Journal:  Alzheimers Res Ther       Date:  2021-12-20       Impact factor: 6.982

8.  Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.

Authors:  Katherine J Kearney; Juliet Butler; Olga M Posada; Clare Wilson; Samantha Heal; Majid Ali; Lewis Hardy; Josefin Ahnström; David Gailani; Richard Foster; Emma Hethershaw; Colin Longstaff; Helen Philippou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.